Glucagon-like peptide-1 receptor agonistsGLP-1RAsCardiovascular diseaseMajor adverse cardiovascular eventsType 2 diabetes mellitusObesityCardiovascular outcome trialsGlucagon-like peptide-1 receptor agonists (GLP-1RAs) are gaining importance due to their effects on cardiovascular parameters. This review ...
近日,德克萨斯大学西南医学中心的研究人员在 Nature 子刊 Nature Communications 上发表了题为:Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease 的研究论文。 该研究发现,与另一类常用的降糖药 DPP-4i 相比,胰高血糖素样肽-1 受体激动剂(GLP1-R...
2024年7月,Nature Medicine杂志发表了一篇研究文章,题为“Long-term kidney Outcomes of Semaglutide in Obesity and Cardiovascular Disease in The SELECT Trial”。研究人员聚焦于肥胖和心血管疾病对肾脏功能的长期影响,还特别关注了一种...
[4]Honigberg MC, Chang LS, McGuire DK, Plutzky J, Aroda VR, Vaduganathan M. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. JAMA Cardiol. 2020;5(10):1182-1190. 更多心血管精彩内容 快来“医生站网页版”瞧一瞧 精彩...
血循环中GLP-1与心脑血管疾病的关系%Evaluation of the relationship between circulating levels of glucagons-like peptide-1 and cardiovascular disease.代谢综合征GLP-1心血管疾病目的 探讨GLP-1与代谢综合征各项指标之间的关系.方法测定静脉血空腹血糖(FBG ) ,高密度脂蛋白胆固醇( HDL-C),低密度脂蛋白(LDL-C...
今日,知名学术期刊《科学》公布胰高血糖素样肽-1(GLP-1)激动剂获选为2023年度科学突破(Science’s 2023 Breakthrough of the Year),这标志着在对抗肥胖症及其相关并发症的长期斗争中的重要里程碑。这项科学成就不仅在肥胖症治疗领域产生了深远影响,而且其潜在应用正被广泛研究,包括在治疗药物成瘾和神经退行性疾病等...
[17]Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. 2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375:311-322. [18]Us...
大量流行病学研究结果证实，超重和肥胖是诱发血脂异常、非酒精性脂肪肝 (Nonalcoholic fatty liver disease, NAFLD)、代谢综合征 (Metabolic syndrome ，MetS )、心血管疾病 (Cardiovascular disease，CVD)、2型糖尿病 (type 2 diabetes mellitus，T2DM)、慢性肾病、多囊卵巢综合征(Polycystic ovary syndrome，PCOS)、...
[17] Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. 2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375:311-322. [18] Ussher, J.R., Drucker, D.J. 2012. Cardiovascular biology of the incre...
3.Paul Edison, M.D., Ph.D., et al. Evaluation of Novel GLP-1 analogue in the treatment of Alzheimer's disease.(Funding: Alzheimer’s Society, UK; Alzheimer’s Drug Discovery Foundation, Novo Nordisk AS, John and Lucille Van Geest Foundation, National Institute for Health and Care Researc...